Short Interest in Mainz Biomed NV (NASDAQ:MYNZ) Increases By 47.4%

Mainz Biomed NV (NASDAQ:MYNZ) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 255,354 shares, a growth of 47.4% from the December 31st total of 173,183 shares. Approximately 2.8% of the shares of the stock are sold short. Based on an average trading volume of 622,087 shares, the days-to-cover ratio is presently 0.4 days. Based on an average trading volume of 622,087 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Mainz Biomed stock. Armistice Capital LLC increased its stake in Mainz Biomed NV (NASDAQ:MYNZ) by 38.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 394,519 shares of the company’s stock after acquiring an additional 109,519 shares during the period. Armistice Capital LLC owned about 7.29% of Mainz Biomed worth $588,000 as of its most recent SEC filing.

Analyst Ratings Changes

A number of analysts have recently issued reports on MYNZ shares. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $14.00.

Mainz Biomed Trading Down 4.0%

MYNZ stock opened at $1.19 on Friday. The company has a market capitalization of $10.78 million, a PE ratio of -0.02 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. Mainz Biomed has a one year low of $0.92 and a one year high of $8.20. The company’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $1.44.

Mainz Biomed (NASDAQ:MYNZ) last announced its quarterly earnings data on Friday, September 26th. The company reported ($1.32) earnings per share (EPS) for the quarter. The firm had revenue of $0.14 million for the quarter. As a group, analysts predict that Mainz Biomed will post -23.6 earnings per share for the current fiscal year.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.